Duet BioTherapeutics is an innovative immuno-oncology organization in the advanced stages of clinical development. They are leading the way in creating bifunctional oligonucleotides to target previously 'undruggable' entities such as STAT3. The company is dedicated to uncovering and advancing therapeutic remedies that enable the human immune system to rejuvenate well-being, even amid seemingly insurmountable, resistant forms of cancer. Duet consolidates the leadership and clinical progression of the immunotherapy assets of Scopus BioPharma and Olimmune, a firm.